Pasar al contenido principal

NANOTERAPIA DIRIGIDA Y RADIOTERAPIA SBRT COMBINADA PARA LA ELIMINACION SELECTIVA DE CELULAS MADRE TUMORALES EN CANCER DE PANCREAS

PI17/00150

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2017
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Centro realización HOSPITAL DE LA SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Latest advances in the development of eukaryotic vaults as targeted drug delivery systems

  • Muñoz Juan, Amanda|||0000-0001-9549-782X
  • Carreño, Aida|||0000-0001-7725-7515
  • Mendoza Moreno, Rosa|||0000-0002-0488-4814
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
The use of smart drug delivery systems (DDSs) is one of the most promising approaches to overcome some of the drawbacks of drug-based therapies, such as improper biodistribution and lack of specific targeting. Some of the most attractive candidates as DDSs are naturally occurring, self-assembling protein nanoparticles, such as viruses, virus-like particles, ferritin cages, bacterial microcompartments, or eukaryotic vaults. Vaults are large ribonucleoprotein nanoparticles present in almost all eukaryotic cells. Expression in different cell factories of recombinant versions of the "major vault protein" (MVP) results in the production of recombinant vaults indistinguishable from native counterparts. Such recombinant vaults can encapsulate virtually any cargo protein, and they can be specifically targeted by engineering the C-terminus of MVP monomer. These properties, together with nanometric size, a lumen large enough to accommodate cargo molecules, biodegradability, biocompatibility and no immunogenicity, has raised the interest in vaults as smart DDSs. In this work we provide an overview of eukaryotic vaults as a new, self-assembling protein-based DDS, focusing in the latest advances in the production and purification of this platform, its application in nanomedicine, and the current preclinical and clinical assays going on based on this nanovehicle.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Selective depletion of metastatic stem cells as therapy for human colorectal cancer

  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Aviñó, Ana|||0000-0003-3047-738X
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Álamo, Patricia|||0000-0003-0510-5701
  • Sala, Rita
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ma Antonia|||0000-0002-1438-8515
  • López Pousa, Antonio|||0000-0003-1066-3951
  • Eritja, Ramon|||0000-0001-5383-9334
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
Selective elimination of metastatic stem cells (MetSCs) promises to block metastatic dissemination. Colorectal cancer (CRC) cells overexpressing CXCR4 display trafficking functions and metastasis-initiating capacity. We assessed the antimetastatic activity of a nanoconjugate (T22-GFP-H6-FdU) that selectively delivers Floxuridine to CXCR4 cells. In contrast to free oligo-FdU, intravenous T22-GFP-H6-FdU selectively accumulates and internalizes in CXCR4 cancer cells, triggering DNA damage and apoptosis, which leads to their selective elimination and to reduced tumor re-initiation capacity. Repeated T22-GFP-H6-FdU administration in cell line and patient-derived CRC models blocks intravasation and completely prevents metastases development in 38-83% of mice, while showing CXCR4 expression-dependent and site-dependent reduction in foci number and size in liver, peritoneal, or lung metastases in the rest of mice, compared to free oligo-FdU. T22-GFP-H6-FdU induces also higher regression of established metastases than free oligo-FdU, with negligible distribution or toxicity in normal tissues. This targeted drug delivery approach yields potent antimetastatic effect, through selective depletion of metastatic CXCR4 cancer cells, and validates metastatic stem cells (MetSCs) as targets for clinical therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Fluorescent dye labeling changes the biodistribution of cell-targeted nanoparticles

  • Álamo, Patricia|||0000-0003-0510-5701
  • Pallarès, Victor|||0000-0002-9851-0345
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Serna, Naroa|||0000-0001-5682-8198
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Morris, Gordon A.|||0000-0003-2588-6349
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ramon|||0000-0003-2661-9525
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
Fluorescent dye labeling is a common strategy to analyze the fate of administered nanoparticles in living organisms. However, to which extent the labeling processes can alter the original nanoparticle biodistribution has been so far neglected. In this work, two widely used fluorescent dye molecules, namely, ATTO488 (ATTO) and Sulfo-Cy5 (S-Cy5), have been covalently attached to a well-characterized CXCR4-targeted self-assembling protein nanoparticle (known as T22-GFP-H6). The biodistribution of labeled T22-GFP-H6-ATTO and T22-GFP-H6-S-Cy5 nanoparticles has been then compared to that of the non-labeled nanoparticle in different CXCR4+ tumor mouse models. We observed that while parental T22-GFP-H6 nanoparticles accumulated mostly and specifically in CXCR4+ tumor cells, labeled T22-GFP-H6-ATTO and T22-GFP-H6-S-Cy5 nanoparticles showed a dramatic change in the biodistribution pattern, accumulating in non-target organs such as liver or kidney while reducing tumor targeting capacity. Therefore, the use of such labeling molecules should be avoided in target and non-target tissue uptake studies during the design and development of targeted nanoscale drug delivery systems, since their effect over the fate of the nanomaterial can lead to considerable miss-interpretations of the actual nanoparticle biodistribution.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

All-in-one biofabrication and loading of recombinant vaults in human cells

  • Martín, Fernando|||0000-0002-3496-9093
  • Carreño, Aida|||0000-0001-7725-7515
  • Mendoza Moreno, Rosa|||0000-0002-0488-4814
  • Caruana Santiago, Pablo|||0000-0002-0170-4355
  • Rodríguez, Francisco|||0000-0001-7909-932X
  • Bravo, Marlon|||0000-0002-0065-9812
  • Benito, Antoni|||0000-0002-9776-1003
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
One of the most promising approaches in the drug delivery field is the use of naturally occurring self-assembling protein nanoparticles, such as virus-like particles, bacterial microcompartments or vault ribonucleoprotein particles as drug delivery systems (DDSs). Among them, eukaryotic vaults show a promising future due to their structural features, in vitro stability and non-immunogenicity. Recombinant vaults are routinely produced in insect cells and purified through several ultracentrifugations, both tedious and time-consuming processes. As an alternative, this work proposes a new approach and protocols for the production of recombinant vaults in human cells by transient gene expression of a His-tagged version of the major vault protein (MVP-H6), the development of new affinity-based purification processes for such recombinant vaults, and the all-in-one biofabrication and encapsulation of a cargo recombinant protein within such vaults by their co-expression in human cells. Protocols proposed here allow the easy and straightforward biofabrication and purification of engineered vaults loaded with virtually any INT-tagged cargo protein, in very short times, paving the way to faster and easier engineering and production of better and more efficient DDS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Nano-based approved pharmaceuticals for cancer treatment, present and future challenges

  • Rodríguez, Francisco|||0000-0001-7909-932X
  • Caruana Santiago, Pablo|||0000-0002-0170-4355
  • De la Fuente, Noa
  • Español, Pia|||0000-0002-1164-6355
  • Gámez, Maria
  • Balart, Josep|||0000-0002-1173-7556
  • Llurba, Elisa|||0000-0003-4048-6407
  • Rovira Negre, Ramon|||0000-0003-4136-4153
  • Ruiz, Raúl
  • Martín-Lorente, Cristina|||0000-0002-9827-0521
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Céspedes, María Virtudes|||0000-0003-2956-5833
Cancer is one of the main causes of death worldwide. To date, and despite the advances in conventional treatment options, therapy in cancer is still far from optimal due to the non-specific systemic biodistribution of antitumor agents. The inadequate drug concentrations at the tumor site led to an increased incidence of multiple drug resistance and the appearance of many severe unde-sirable side effects. Nanotechnology, through the development of nanoscale-based pharmaceuticals, has emerged to provide new and innovative drugs to overcome these limitations. In this review, we provide an overview of the approved nanomedicine for cancer treatment and the rationale behind their designs and applications. We also highlight the new approaches that are currently under investigation and the perspectives and challenges for nanopharmaceuticals, focusing on the tumor microenvironment and tumor disseminate cells as the most attractive and effective strategies for cancer treatments.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Escherichia coli as a New Platform for the Fast Production of Vault-like Nanoparticles, An Optimized Protocol

  • Fernández, Roger
  • Carreño, Aida|||0000-0001-7725-7515
  • Mendoza Moreno, Rosa|||0000-0002-0488-4814
  • Benito, Antoni|||0000-0002-9776-1003
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
Vaults are protein nanoparticles that are found in almost all eukaryotic cells but are absent in prokaryotic ones. Due to their properties (nanometric size, biodegradability, biocompatibility, and lack of immunogenicity), vaults show enormous potential as a bio-inspired, self-assembled drug-delivery system (DDS). Vault architecture is directed by self-assembly of the "major vault protein" (MVP), the main component of this nanoparticle. Recombinant expression (in different eukaryotic systems) of the MVP resulted in the formation of nanoparticles that were indistinguishable from native vaults. Nowadays, recombinant vaults for different applications are routinely produced in insect cells and purified by successive ultracentrifugations, which are both tedious and time-consuming strategies. To offer cost-efficient and faster protocols for nanoparticle production, we propose the production of vault-like nanoparticles in Escherichia coli cells, which are still one of the most widely used prokaryotic cell factories for recombinant protein production. The strategy proposed allowed for the spontaneous encapsulation of the engineered cargo protein within the self-assembled vault-like nanoparticles by simply mixing the clarified lysates of the producing cells. Combined with well-established affinity chromatography purification methods, our approach contains faster, cost-efficient procedures for biofabrication in a well-known microbial cell factory and the purification of "ready-to-use" loaded protein nanoparticles, thereby opening the way to faster and easier engineering and production of vault-based DDSs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Neural plasticity of the uterus, New targets for endometrial cancer?

  • Español, Pia|||0000-0002-1164-6355
  • Luna-Guibourg, Rocío|||0000-0003-4861-8339
  • Soler, Cristina
  • Caruana Santiago, Pablo|||0000-0002-0170-4355
  • Altés-Arranz, Amanda
  • Rodríguez-Lozano, Francisco|||0000-0002-1503-0750
  • Porta, Oriol|||0000-0001-6000-9566
  • Sánchez García, Olga|||0000-0002-5279-440X
  • Llurba, Elisa|||0000-0003-4048-6407
  • Rovira Negre, Ramon|||0000-0003-4136-4153
  • Céspedes, María Virtudes|||0000-0003-2956-5833
Endometrial carcinoma is the most common gynecological malignancy in Western countries and is expected to increase in the following years because of the high index of obesity in the population. Recently, neural signaling has been recognized as part of the tumor microenvironment, playing an active role in tumor progression and invasion of different solid tumor types. The uterus stands out for the physiological plasticity of its peripheral nerves due to cyclic remodeling brought on by estrogen and progesterone hormones throughout the reproductive cycle. Therefore, a precise understanding of nerve-cancer crosstalk and the contribution of the organ-intrinsic neuroplasticity, mediated by estrogen and progesterone, of the uterine is urgently needed. The development of new and innovative medicines for patients with endometrial cancer would increase their quality of life and health. This review compiles information on the architecture and function of autonomous uterine neural innervations and the influence of hormone-dependent nerves in normal uterus and tumor progression. It also explores new therapeutic possibilities for endometrial cancer using these endocrine and neural advantages.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tuning plasmid DNA amounts for cost-effective transfections of mammalian cells, when less is more

  • Carreño, Aida|||0000-0001-7725-7515
  • Guerrero-Yagüe, Rubén|||0000-0002-6012-2734
  • Casal, Enriqueta|||0000-0002-0334-0380
  • Mendoza, Rosa|||0000-0002-0488-4814
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
Transient gene expression (TGE) in mammalian cells is a well-known approach to the fast expression of recombinant proteins. The human cell line HEK (human embryonic kidney) 293F is widely used in this field, due to its adaptability to grow in suspension to high cell densities in serum-free media, amenability to transfection, and production of recombinant proteins in satisfactory quantities for functional and structural analysis. Amounts of plasmid DNA (pDNA) required in transfections for TGE remain high (usually 1 µg pDNA/mL, or even higher), representing a noticeable proportion of the overall cost. Thus, there is an economic need to reduce amounts of coding pDNA in TGE processes. In this work, amounts of both pDNA and transfecting agent used for TGE in HEK 293F cells have been explored in order to reduce them without compromising (or even improving) the productivity of the process in terms of protein yield. In our hands, minimal polyethyleneimine (PEI) cytotoxicity and optimum protein yields were obtained when transfecting at 0.5 µg pDNA/mL (equal to 0.5 µg pDNA/million cells) and a DNA-to-PEI ratio of 1:3, a trend confirmed for several unrelated recombinant proteins. Thus, carefully tuning pDNA and transfecting agent amounts not only reduces the economic costs but also results in higher recombinant protein yields. These results surely have a direct application and interest for the biopharmaceutical industry, always concerned in increasing productivity while decreasing economic costs. • Mammalian cells are widely used to produce recombinant proteins in short times. • Tuning DNA and transfecting agent are of great interest to optimize economic costs. • Reducing DNA and transfecting agent amounts result in higher protein yields.